HaloSciton debuted Halo, the first-ever hybrid fractional laser, at the 72nd annual meeting of the American Academy of Dermatology in Denver.

Halo promises fractional ablative results with nonablative downtime by applying both wavelengths in a single pass to the same microscopic treatment zone: 1470 nanometers (nm) for coagulation and 2940 nm for ablation. The 1470-nm wavelength is used for delivering between 100 and 700 microns of coagulation to the epidermis and dermis, where solar damage exists. The 2940-nm wavelength is used to deliver from 0 to 100 microns of ablation to the epidermis.

This duality gives Halo the unique ability to provide separate treatments for the epidermis and dermis.

Halo is available on the JOULE platform.